Charles River Laboratories International (CRL)
(Delayed Data from NYSE)
$205.27 USD
+3.94 (1.96%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $205.42 +0.15 (0.07%) 7:58 PM ET
4-Sell of 5 4
B Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$205.27 USD
+3.94 (1.96%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $205.42 +0.15 (0.07%) 7:58 PM ET
4-Sell of 5 4
B Value C Growth B Momentum C VGM
Zacks News
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Charles River (CRL) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Robust demand for research models and the Vigene Biosciences buyout are likely to have contributed to growth for Charles River (CRL).
Charles River Laboratories (CRL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Charles River (CRL) to Offer Cryo-EM Capabilities With New Pact
by Zacks Equity Research
Charles River's (CRL) recent partnership will enable the company to improve drug discovery projects by allowing structure-based design for a greater portfolio of targets.
Here's Why You Should Invest in Charles River (CRL) Now
by Zacks Equity Research
Investors are optimistic about Charles River (CRL) on solid second-quarter performance and bullish 2021 guidance.
Why Is Charles River (CRL) Up 9.5% Since Last Earnings Report?
by Zacks Equity Research
Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Charles River (CRL) at a 52-Week High: What's Driving It?
by Zacks Equity Research
Charles River (CRL) ended the second quarter on a strong note with solid performance by the RMS, DSA and Manufacturing Support arms driving the top line.
MODV or CRL: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MODV vs. CRL: Which Stock Is the Better Value Option?
Charles River (CRL) Q2 Earnings Beat Estimates, 2021 View Up
by Zacks Equity Research
Robust performance by all three segments drove Charles River's (CRL) revenues in the second quarter.
Charles River Laboratories (CRL) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Charles River (CRL) delivered earnings and revenue surprises of 9.21% and 5.17%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Charles River (CRL) Q2 Earnings to Mirror Broad-Based Demand
by Zacks Equity Research
Charles River's (CRL) biotech clients are likely to have benefited from a robust funding environment in Q2.
Charles River Laboratories (CRL) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charles River (CRL) at a 52-Week High: What's Driving It?
by Zacks Equity Research
Strong performance by the RMS, DSA and Manufacturing segments is driving the top line for Charles River (CRL).
10 Top-Ranked Stocks Powering S&P 500 ETF
by Sweta Killa
The S&P 500 has been outperforming this year due to the strength in value and cyclical stocks, which were battered last year in the pandemic.
Charles River (CRL) Advances in Gene Therapy With Vigene Buyout
by Zacks Equity Research
The consolidation between Charles River (CRL) and Vigene is set to establish an end-to-end, gene-modified cell therapy solution in the United States.
What Makes Charles River Laboratories (CRL) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Charles River Laboratories (CRL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Duke Energy (DUK) Brand Starts Building 250MW Solar Project
by Zacks Equity Research
Duke Energy (DUK) announces the 250-MW Pisgah Ridge Solar project will supply power to three corporations, once its construction is completed by 2022-end.
Charles River Laboratories (CRL) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Charles River (CRL) delivered earnings and revenue surprises of 15.53% and 3.49%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
ETF Strategies to Hedge Against Inflation
by Neena Mishra
Here are some ways to protect your portfolio from rising inflation.
Teladoc (TDOC) Q4 Loss Widens, Revenues Surpass Estimates
by Zacks Equity Research
Teladoc's (TDOC) Q4 earnings result reflects revenue gains, more than offset by flared-up expenses.
Company News for Feb 18, 2021
by Zacks Equity Research
Companies in the news are: CRL, VIR, LODE, CLPS
Charles River Laboratories (CRL) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Charles River (CRL) delivered earnings and revenue surprises of 12.74% and 4.63%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Charles River Laboratories (CRL) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is a Beat in the Cards for CVS Health (CVS) in Q4 Earnings?
by Zacks Equity Research
Through November and December, the resurgence of new COVID-19 cases might have resulted in more COVID-19 tests conducts by CVS Health (CVS).